SGCB and cirrhosis of liver: Similarly, as demonstrated by Hall et al. (2019) [49] in CCl4-induced liver cirrhosis, the sGC stimulator praliciguat markedly increased hepatic cGMP levels and reduced fibrosis and inflammation in the damaged liver.